Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
BioCryst Pharmaceuticals Inc
BCRXCurrent price
7.98 USD
-0.17 USD (-2.09%)
Last closed
8.13 USD
Company
www.biocryst.com
ISIN
US09058V1035
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 797 839 232 USD
Yield for 12 month
+16.50 %
1Y
3Y
5Y
10Y
15Y
BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Address: 4505 Emperor Boulevard, Durham, NC, United States, 27703
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
14.45 USDP/E ratio
–Dividend Yield
–Current Year
+331 412 000 USD
Last Year
+270 827 000 USD
Current Quarter
+109 332 000 USD
Last Quarter
+92 761 000 USD
Current Year
+325 096 000 USD
Last Year
+264 233 000 USD
Current Quarter
+107 278 001 USD
Last Quarter
+91 496 000 USD
Key Figures BCRX
1 year
3 years
5 years
10 years
EBITDA
-52 709 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-6.91 %
PEG Ratio
-0.28
Return On Equity TTM
-1925.37 %
Wall Street Target Price
14.45 USD
Revenue TTM
382 236 000 USD
Book Value
-2.3 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
32.5 %
Dividend Yield
–
Gross Profit TTM
10 936 000 USD
Earnings per share
-0.73 USD
Diluted Eps TTM
-0.73 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-38.18 %
Dividend Analytics BCRX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BCRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation BCRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
6.1414
Price Sales TTM
4.7035
Enterprise Value EBITDA
-12.2018
Price Book MRQ
56.5858
Financials BCRX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BCRX
For 52 weeks
4.03 USD
8.84 USD
50 Day MA
7.33 USD
Shares Short Prior Month
24 384 903
200 Day MA
6.02 USD
Short Ratio
9.06
Shares Short
24 805 829
Short Percent
12.09 %
BeatStart